Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma

Ruwanthi Kolamunnage-Dona, Sarah Berhane, Harry Potts, Edward H Williams, James Tanner, Tobias Janowitz, Matthew Hoare, Philip Johnson

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences